These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 2300926)

  • 1. Production of chemotactic peptides by neutrophil degradation of heparin cofactor II.
    Corbin LW; Church FC; Hoffman M
    Thromb Res; 1990 Jan; 57(1):77-85. PubMed ID: 2300926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristics of the chemotactic activity of heparin cofactor II proteolysis products.
    Hoffman M; Pratt CW; Corbin LW; Church FC
    J Leukoc Biol; 1990 Aug; 48(2):156-62. PubMed ID: 2196322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leukocyte chemoattractant peptides from the serpin heparin cofactor II.
    Church FC; Pratt CW; Hoffman M
    J Biol Chem; 1991 Jan; 266(2):704-9. PubMed ID: 1985958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heparin cofactor II-proteinase reaction products exhibit neutrophil chemoattractant activity.
    Hoffman M; Pratt CW; Brown RL; Church FC
    Blood; 1989 May; 73(6):1682-5. PubMed ID: 2713501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction of heparin cofactor II with neutrophil elastase and cathepsin G.
    Pratt CW; Tobin RB; Church FC
    J Biol Chem; 1990 Apr; 265(11):6092-7. PubMed ID: 2318847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thrombin inhibition by HCII in the presence of elastase-cleaved HCII and thrombin-HCII complex.
    Maekawa H; Sato H; Tollefsen DM
    Thromb Res; 2000 Dec; 100(5):443-51. PubMed ID: 11150588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Site-directed mutagenesis of arginine 103 and lysine 185 in the proposed glycosaminoglycan-binding site of heparin cofactor II.
    Blinder MA; Tollefsen DM
    J Biol Chem; 1990 Jan; 265(1):286-91. PubMed ID: 2104620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heparin cofactor II is regulated allosterically and not primarily by template effects. Studies with mutant thrombins and glycosaminoglycans.
    Sheehan JP; Tollefsen DM; Sadler JE
    J Biol Chem; 1994 Dec; 269(52):32747-51. PubMed ID: 7806495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contribution of basic residues of the A helix of heparin cofactor II to heparin- or dermatan sulfate-mediated thrombin inhibition.
    Hayakawa Y; Hirashima Y; Kurimoto M; Hayashi N; Hamada H; Kuwayama N; Endo S
    FEBS Lett; 2002 Jul; 522(1-3):147-50. PubMed ID: 12095635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heparin cofactor IIOslo. Mutation of Arg-189 to His decreases the affinity for dermatan sulfate.
    Blinder MA; Andersson TR; Abildgaard U; Tollefsen DM
    J Biol Chem; 1989 Mar; 264(9):5128-33. PubMed ID: 2647747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The protease specificity of heparin cofactor II. Inhibition of thrombin generated during coagulation.
    Parker KA; Tollefsen DM
    J Biol Chem; 1985 Mar; 260(6):3501-5. PubMed ID: 3838315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of heparin cofactor II-derived chemotaxins on neutrophil actin conformation and cyclic AMP levels.
    Hoffman M; Faulkner KA; Iannone MA; Church FC
    Biochim Biophys Acta; 1991 Oct; 1095(1):78-82. PubMed ID: 1932129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The interaction of glycosaminoglycans with heparin cofactor II: structure and activity of a high-affinity dermatan sulfate hexasaccharide.
    Tollefsen DM
    Adv Exp Med Biol; 1992; 313():167-76. PubMed ID: 1442260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N-Acetylgalactosamine 4,6-O-sulfate residues mediate binding and activation of heparin cofactor II by porcine mucosal dermatan sulfate.
    Halldórsdóttir AM; Zhang L; Tollefsen DM
    Glycobiology; 2006 Aug; 16(8):693-701. PubMed ID: 16624894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Arterial smooth muscle cell heparan sulfate proteoglycans accelerate thrombin inhibition by heparin cofactor II.
    Shirk RA; Church FC; Wagner WD
    Arterioscler Thromb Vasc Biol; 1996 Sep; 16(9):1138-46. PubMed ID: 8792767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Heparin cofactor II, a thrombin inhibitor with a still not clarified physiologic role].
    Rossi EB; Duboscq CL; Kordich LC
    Medicina (B Aires); 1999; 59(1):95-104. PubMed ID: 10349131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Altering heparin cofactor II at VAL439 (P6) either impairs inhibition of thrombin or confers elastase resistance.
    Cunningham MA; Bhakta V; Sheffield WP
    Thromb Haemost; 2002 Jul; 88(1):89-97. PubMed ID: 12152684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Altered dermatan sulfate structure and reduced heparin cofactor II-stimulating activity of biglycan and decorin from human atherosclerotic plaque.
    Shirk RA; Parthasarathy N; San Antonio JD; Church FC; Wagner WD
    J Biol Chem; 2000 Jun; 275(24):18085-92. PubMed ID: 10749870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of heparin cofactor II activity by glycosaminoglycans and adhesive glycoproteins.
    Petzelbauer E; Seiffert D; Beckmann R; Pusch B; Geiger M; Binder BR
    Thromb Res; 1992 Jun; 66(5):559-67. PubMed ID: 1381850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heparin facilitates dissociation of complexes between thrombin and a reactive site mutant (L444R) of heparin cofactor II.
    Han JH; Van Deerlin VM; Tollefsen DM
    J Biol Chem; 1997 Mar; 272(13):8243-9. PubMed ID: 9079643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.